Back
Zevra Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
ZVRA
Sponsored
Yours Free! Top SIX AI Dividend Stocks Right Now
NO CREDIT CARD REQUIRED!
Buy
67
ZVRA
Zevra Therapeutics
Last Price:
8.81
Seasonality Move:
3.19%
7 Day Trial
ALL ACCESS PASS
$
7
U.S. Government Report Alert Tuesday
Discover the Secret LoopholeZevra Therapeutics Price Quote
$8.81
+0.20 (+2.32%)
(Updated: November 6, 2024 at 5:55 PM ET)
Zevra Therapeutics Key Stats
Buy
67
Zevra Therapeutics (ZVRA)
is a Buy
Day range:
$8.26 - $8.65
52-week range:
$3.89 - $8.95
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
14.35
P/B ratio:
13.95%
Volume:
426K
Avg. volume:
811.2K
1-year change:
85.96%
Market cap:
$453M
Revenue:
$27.5M
EPS:
$-1.68
How Much Does Zevra Therapeutics Make?
-
How Much Are Zevra Therapeutics's Sales Annually?
ZVRA Revenues are $27.5M -
How Much Profit Does Zevra Therapeutics's Make A Year?
ZVRA net income is -$46M
Is Zevra Therapeutics Growing As A Company?
-
What Is Zevra Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.47% -
What Is Zevra Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Zevra Therapeutics Stock Price Performance
-
Did Zevra Therapeutics Stock Go Up Last Month?
Zevra Therapeutics share price went up by 19.58% last month -
Did ZVRA's Share Price Rise Over The Last Year?
ZVRA share price rose by 85.96% over the past 1 year
What Is Zevra Therapeutics 52-Week High & Low?
-
What Is Zevra Therapeutics’s 52-Week High Share Price?
Zevra Therapeutics has traded as high as $8.95 over the past 52 weeks -
What Is Zevra Therapeutics’s 52-Week Low Share Price?
Zevra Therapeutics has traded as low as $3.89 over the past 52 weeks
Zevra Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Zevra Therapeutics?
-
How Much Debt Does Zevra Therapeutics Have?
Total long term debt quarterly is $58.3M -
How Much Cash Does Zevra Therapeutics Have?
Cash and short term investments quarterly total is $49.3M -
What Is Zevra Therapeutics’s Book Value Per Share?
Book value per share is 0.77
Is Zevra Therapeutics Cash Flow Positive?
-
What Is ZVRA Cash Flow From Operations?
Cash flow from operations (TTM) is -$56.1M -
What Is Zevra Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $47.8M -
What Is Zevra Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$19.2M
Zevra Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
ZVRA return on invested capital is -68.51% -
What Is Zevra Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -46.14% -
What Is ZVRA Return On Equity?
ROE is a measure of profitability and is -117.77%
Zevra Therapeutics Earnings Date & Stock Price
-
What Is Zevra Therapeutics's Stock Price Today?
A single share of ZVRA can be purchased today for 8.61 -
What Is Zevra Therapeutics’s Stock Symbol?
Zevra Therapeutics trades on the nasdaq under the ticker symbol: ZVRA -
When Is Zevra Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Zevra Therapeutics is scheduled on November 12, 2024 -
When Is ZVRA's next ex-dividend date?
Zevra Therapeutics's next ex-dividend date is November 7, 2024 -
How To Buy Zevra Therapeutics Stock?
You can buy Zevra Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Zevra Therapeutics Competitors
-
Who Are Zevra Therapeutics's Competitors?
Below is a list of companies who compete with Zevra Therapeutics or are related in some way:
Zevra Therapeutics Dividend Yield
-
What Is ZVRA Dividend Yield?
Zevra Therapeutics’s dividend yield currently is 0% -
What Is Zevra Therapeutics’s Payout Ratio?
Zevra Therapeutics’s payout ratio is 0% -
When Did Zevra Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 7, 2024 -
What Is Zevra Therapeutics’s Dividend Per Share?
Zevra Therapeutics pays a dividend of $0.00 per share
Zevra Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -9.92% |
Revenue: | -47.47% | 2.09% |
Analyst Recommendations
Buy Recommendations: | 4 |
---|---|
Hold Recommendations: | 0 |
Sell Recommendations: | 0 |
Price Target: | 20.43 |
Upside from Last Price: | 137.27% |